FOLD News and Press, Amicus Therapeutics Inc. From 11/08/23

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafol d ® Quarterly Revenue Surpasses $100M for the First Time Increasing FY 2023 Galafol d ® Revenue Growth Guidance to 16%...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Amicus Therapeutics Inc. (FOLD) is expected to report $-0.08 for Q3 2023

2023-11-07 11:53:49 ET More on Amicus Therapeutics Amicus Therapeutics: The Right Play Now Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter Amicus: Holding Until AT-GAA U.S. Approval Amicus in pact with Blackstone for $43...

PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. UBS Biopharma Conference in Miami, FL on Thursday, November 9, 2023, at 1:00 ...

2023-10-31 12:24:58 ET Summary Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Opfolda for Pompe disease. Amicus Therapeutics i...

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2023. ...

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS) , being ...

2023-10-02 09:34:12 ET More on Blackstone, Amicus, etc. Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter Blackstone Surges From A Solid Foundation (Technical Analysis) Blackstone Stock: 3 Reasons To Sell It Right Now Blac...

Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focus...